Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma
Surgical resection remains the cornerstone of curative treatment for intrahepatic cholangiocarcinoma (iCCA), but this option is only available to a small percentage of patients. For patients with unresectable iCCA, systemic therapy with gemcitabine and platinum-based agents represents the mainstay o...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/14/2/217 |
| _version_ | 1827343273792897024 |
|---|---|
| author | Gregory Woodhead Sean Lee Lucas Struycken Daniel Goldberg Jack Hannallah Shamar Young |
| author_facet | Gregory Woodhead Sean Lee Lucas Struycken Daniel Goldberg Jack Hannallah Shamar Young |
| author_sort | Gregory Woodhead |
| collection | DOAJ |
| description | Surgical resection remains the cornerstone of curative treatment for intrahepatic cholangiocarcinoma (iCCA), but this option is only available to a small percentage of patients. For patients with unresectable iCCA, systemic therapy with gemcitabine and platinum-based agents represents the mainstay of treatment; however, the armamentarium has grown to include targeted molecular therapies (e.g., FGFR2 inhibitors), use of adjuvant therapy, liver transplantation in select cases, immunotherapy, and locoregional liver-directed therapies. Despite advances, iCCA remains a challenge due to the advanced stage of many patients at diagnosis. Furthermore, given the improving options for systemic therapy and the fact that the majority of iCCA patients succumb to disease progression in the liver, the role of locoregional therapies has increased. This review will focus on the expanding role of interventional radiology and liver-directed therapies in the treatment of iCCA. |
| first_indexed | 2024-03-07T22:23:53Z |
| format | Article |
| id | doaj.art-8743aba886774b848daba97b1058f21e |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-07T22:23:53Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-8743aba886774b848daba97b1058f21e2024-02-23T15:24:40ZengMDPI AGLife2075-17292024-02-0114221710.3390/life14020217Interventional Radiology Locoregional Therapies for Intrahepatic CholangiocarcinomaGregory Woodhead0Sean Lee1Lucas Struycken2Daniel Goldberg3Jack Hannallah4Shamar Young5Department of Medical Imaging, Division of Interventional Radiology, University of Arizona Medical Center, Tucson, AZ 85712, USADepartment of Basic Biomedical Sciences, Touro College of Osteopathic Medicine, Middletown, NY 10027, USADepartment of Medical Imaging, Division of Interventional Radiology, University of Arizona Medical Center, Tucson, AZ 85712, USADepartment of Medical Imaging, Division of Interventional Radiology, University of Arizona Medical Center, Tucson, AZ 85712, USADepartment of Medical Imaging, Division of Interventional Radiology, University of Arizona Medical Center, Tucson, AZ 85712, USADepartment of Medical Imaging, Division of Interventional Radiology, University of Arizona Medical Center, Tucson, AZ 85712, USASurgical resection remains the cornerstone of curative treatment for intrahepatic cholangiocarcinoma (iCCA), but this option is only available to a small percentage of patients. For patients with unresectable iCCA, systemic therapy with gemcitabine and platinum-based agents represents the mainstay of treatment; however, the armamentarium has grown to include targeted molecular therapies (e.g., FGFR2 inhibitors), use of adjuvant therapy, liver transplantation in select cases, immunotherapy, and locoregional liver-directed therapies. Despite advances, iCCA remains a challenge due to the advanced stage of many patients at diagnosis. Furthermore, given the improving options for systemic therapy and the fact that the majority of iCCA patients succumb to disease progression in the liver, the role of locoregional therapies has increased. This review will focus on the expanding role of interventional radiology and liver-directed therapies in the treatment of iCCA.https://www.mdpi.com/2075-1729/14/2/217intrahepatic cholangiocarcinomaY90SIRTTACEcryoablationmicrowave ablation |
| spellingShingle | Gregory Woodhead Sean Lee Lucas Struycken Daniel Goldberg Jack Hannallah Shamar Young Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma Life intrahepatic cholangiocarcinoma Y90 SIRT TACE cryoablation microwave ablation |
| title | Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma |
| title_full | Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma |
| title_fullStr | Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma |
| title_full_unstemmed | Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma |
| title_short | Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma |
| title_sort | interventional radiology locoregional therapies for intrahepatic cholangiocarcinoma |
| topic | intrahepatic cholangiocarcinoma Y90 SIRT TACE cryoablation microwave ablation |
| url | https://www.mdpi.com/2075-1729/14/2/217 |
| work_keys_str_mv | AT gregorywoodhead interventionalradiologylocoregionaltherapiesforintrahepaticcholangiocarcinoma AT seanlee interventionalradiologylocoregionaltherapiesforintrahepaticcholangiocarcinoma AT lucasstruycken interventionalradiologylocoregionaltherapiesforintrahepaticcholangiocarcinoma AT danielgoldberg interventionalradiologylocoregionaltherapiesforintrahepaticcholangiocarcinoma AT jackhannallah interventionalradiologylocoregionaltherapiesforintrahepaticcholangiocarcinoma AT shamaryoung interventionalradiologylocoregionaltherapiesforintrahepaticcholangiocarcinoma |